Comparison of patients' characteristics
| Characteristics . | Cladribine (2-CdA) + P (%) . | Chlorambucil + P (%) . | P . |
|---|---|---|---|
| No. = 229 (100%) | 126 (55) | 103 (45) | .6 |
| Sex | |||
| Male | 86 (68) | 67 (65) | .6 |
| Female | 40 (32) | 36 (35) | |
| Age (y) (median, range) | 61 (31-92) | 62 (31-88) | .5 |
| Rai stage at diagnosis | |||
| 0 | 18 (14) | 13 (13) | |
| I + II | 60 (48) | 61 (59) | .2 |
| III + IV | 48 (38) | 28 (28) | |
| Disease duration (mo) (median, range) | 25.5 (3-103) | 25.0 (3-145) | .8 |
| Pretreatment laboratory values (median, range) | |||
| WBC (×109/L) | 81.3 (25.4-376.8) | 66.4 (26.2-525.0) | .04 |
| Lymphocytes (×109/L) | 73.9 (25.4-376.8) | 59.0 (19.7-519.7) | .2 |
| Granulocytes (×109/L) | 5.7 (0-6.2) | 5.3 (0.1-8.9) | .2 |
| Hemoglobin (g/dL) | 12.3 (5.4-16.7) | 12.7 (3.7-16.3) | .4 |
| Platelets (×109/L) | 145.0 (20.0-384.0) | 148.5 (30.0-585.0) | .3 |
| Characteristics . | Cladribine (2-CdA) + P (%) . | Chlorambucil + P (%) . | P . |
|---|---|---|---|
| No. = 229 (100%) | 126 (55) | 103 (45) | .6 |
| Sex | |||
| Male | 86 (68) | 67 (65) | .6 |
| Female | 40 (32) | 36 (35) | |
| Age (y) (median, range) | 61 (31-92) | 62 (31-88) | .5 |
| Rai stage at diagnosis | |||
| 0 | 18 (14) | 13 (13) | |
| I + II | 60 (48) | 61 (59) | .2 |
| III + IV | 48 (38) | 28 (28) | |
| Disease duration (mo) (median, range) | 25.5 (3-103) | 25.0 (3-145) | .8 |
| Pretreatment laboratory values (median, range) | |||
| WBC (×109/L) | 81.3 (25.4-376.8) | 66.4 (26.2-525.0) | .04 |
| Lymphocytes (×109/L) | 73.9 (25.4-376.8) | 59.0 (19.7-519.7) | .2 |
| Granulocytes (×109/L) | 5.7 (0-6.2) | 5.3 (0.1-8.9) | .2 |
| Hemoglobin (g/dL) | 12.3 (5.4-16.7) | 12.7 (3.7-16.3) | .4 |
| Platelets (×109/L) | 145.0 (20.0-384.0) | 148.5 (30.0-585.0) | .3 |
WBC, white blood cell count.